Analysis of PKC-ζ protein levels in normal and malignant breast tissue subtypes

TRACESS SMALLEY, S. M. ANISUL ISLAM, CHRISTOPHER APOSTOLATOS, ANDRÉ APOSTOLATOS and MILDRED ACEVEDO-DUNCAN

Department of Chemistry, The University of South Florida, Tampa, FL 33620, USA

Received February 16, 2018; Accepted November 9, 2018

DOI: 10.3892/ol.2018.9792

Abstract. It is estimated that breast cancer will be the second leading cause of cancer-associated mortality in women in 2018. Previous research has demonstrated that the atypical protein kinase C-ζ (PKC-ζ) is a component of numerous dysregulated pathways in breast cancer, including cellular proliferation, survival, and cell cycle upregulation. The present study investigated the PKC-ζ protein in breast tissue to evaluate its potential as a biomarker for breast cancer invasion, and demonstrated that an overexpression of PKC-ζ protein can be indicative of carcinogenesis. The present study analyzed the expression of PKC-ζ in individuals with no tumor complications and malignant female human breast tissue samples (lobular carcinoma in situ, invasive lobular carcinoma, ductal carcinoma in situ and invasive ductal carcinoma) with the use of western blot analysis, immunohistochemistry and statistical analysis (83 samples). The present study also evaluated the invasive behavior of MDA-MB-231 breast cancer cells following the knockdown of PKC-ζ with a Transwell invasion assay and an immunofluorescent probe for filamentous actin (F-actin) organization. The data demonstrated that PKC-ζ expression was identified to be higher in invading tissues when compared with non-invading tissues. The results also suggest that PKC-ζ is more abundant in ductal tissues when compared with lobular tissues. In addition, the protein studies also suggest that PKC-ζ is a component for invasive behavior through the Ras-related C3 botulinum toxin substrate 1 (Rac1) and Ras homolog gene family member A (RhoA) pathway, and PKC-ζ is required for the F-actin reorganization in invasive cells. Therefore, PKC-ζ should be considered to be a biomarker in the development of breast cancer as well as an indicator of invading tumor cells.

Introduction

In the current research, cancer statistics show that invasive breast cancer is projected to have 234,190 new cases and deaths, for which 231,840 will be women (1). Approximately 40,290 women will die from invasive breast cancer in 2018 (2). Although the percentage of mortalities has decreased over the last few years, breast cancer still ranks as the second leading cause of cancer death in women; treatments usually entail invasive surgeries, including breast-conserving surgeries and mastectomies (1). From a clinical standpoint, invasive ductal carcinoma (IDC) is the most common form of breast cancer, affecting 50-75% of breast cancer diagnoses (2). Breast cancer is a heterogeneous disease, and research has shown that the top mutated genes in breast carcinomas and carcinomas in situ are Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit (PIK3CA), Tumor Protein P53 (TP53), and E-cadherin (CDH1) (3). However, this investigation shows a link between protein kinase C-ζ (PKC-ζ) protein overexpression and breast cancer development, particularly in invasive behavior. For this reason, breast cancer biomarkers are of interest, as they may help to predict breast cancer incidents and contribute to better therapeutic regimens.

The complete understanding of histological and pathological features of the lobular and ductal carcinomas are far from full elucidation. In an investigation by Ruibal et al, the authors concluded that, in the absence of the axillary node, lobular carcinomas had a higher concentration of breast cancer estrogen-inducible protein (pS2) than ductal carcinomas (2). Lobular carcinomas were also shown to have a higher frequency of diploidy, which suggests that lobular carcinomas are less aggressive and grow slower (4).

An overexpression of PKC-ζ protein promotes carcinogenesis by stimulating cancer cell proliferation through pathways such as the Nuclear factor-kB (NF-kB), which plays an essential role in cancer initiation and progression (5). Previous studies suggest that PKC-ζ is a regulatory factor for the nuclear translocation of NF-kB that in turn represses E-cadherin (6,7). Although the link between the loss of E-cadherin and cancer prognosis remains ambiguous, recent findings showed that E-cadherin possesses a vital tumor suppressive role (8). Moreover, some researchers
have paralleled PKC-ζ to the phosphorylation of the Inhibitor of κB kinase (IKK) complex, which in turn phosphorylates the Inhibitor of κB (IkB) and triggers IkB degradation (7,9). The degradation of IkB releases NF-κB, allowing its translocation from the cytosol into the nucleus, where it functions as a transcription factor (9). The transcription factor applies explicitly to targets such as apoptosis regulators and stress response genes. Furthermore, studies show that NF-κB also plays a role in epithelial to mesenchymal transition, a crucial carcinogenic event (7).

PKC-ζ has also been linked to metastatic behaviors of cancer cells. In a study by Islam et al., the Ras-related C3 botulinum toxin substrate 1 (Rac1)/Pak1/β-Catenin signaling cascade in colorectal cancer cell lines was evaluated after the inhibition of PKC-ζ (10). The knockdown of PKC-ζ decreased the nuclear translocation of β-Catenin which ultimately leads to reduced colorectal cell proliferation and metastasis (10). These data were further supported by another investigation performed by Wu et al., which determined that inhibition of PKC-ζ in breast cancer cell lines decreased adhesion and actin polymerization (11). These studies advocate the theory that PKC-ζ as a critical component of the invasive behaviors of cancer cells.

Although PKC-ζ has been studied in invasive breast cancers (most commonly ductal), there have been no examinations of PKC-ζ expression in other types of breast cancer (such as carcinomas in situ). An investigation by Lin et al. confirmed that atypical PKC isoforms were elevated in breast cancer tissues (IDC, specifically) when compared to adjacent healthy breast tissue (12). Additionally, Schöndorf et al. determined that antineoplastic agents affect the activation of PKC in IDC breast cancer tumors (13). In this study, our focus was to further investigate the PKC-ζ expression profile in the four histological subtypes of breast cancer such as lobular carcinoma in situ (LCIS), invasive lobular carcinoma (ILC), ductal carcinoma in situ (DCIS) and IDC. We also evaluated the difference in the PKC-ζ expression among healthy, invasive and non-invasive tissues. Moreover, the invasive characteristics of MDA-MB-231 breast cancer cells were examined upon the inhibition of PKC-ζ. We found that PKC-ζ is overexpressed in IDC and ILC tissue specimens compared to other subtypes. In addition, the inhibition of PKC-ζ decreased the invasion of MDA-MB-231 breast cancer cells.

**Materials and methods**

**Specimen collection and tissue fractionation.** The NCI-supported Cooperative Human Tissue Network (CHTN; Birmingham, AL, USA) collected and provided the breast tissue samples (normal, LCIS, ILC, DCIS, and IDC). The specimens were collected and snap-frozen in liquid nitrogen or placed in dry ice and stored in a liquid nitrogen vapor phase freezer (-196°C), where the tissues stayed until shipment. The tissues were shipped in dry ice. Formalin-fixed paraffin-embedded tissues (FFPE) were also provided for immunohistochemistry staining. Tissues were selected based on their histological features (normal, LCIS, ILC, DCIS, and IDC). The mean age of patient samples collected was 51 years and the collection period of the samples was 2001-2015. Normal tissues were selected from breast reduction patients with no previous diagnosis of cancer or the area adjacent to a patient’s malignant tumors. Patients with DCIS and LCIS were selected based on the lack of invasive tissue adjacent to the extraction site; some tissues were taken from patients with invasive tissues in the opposite breast.

The tissue specimens were then resuspended and sonicated for 3×5 sec cycles on ice in 1 ml of homogenization buffer (Pierce® Immuno Precipitation Lysis Buffer, 25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40 and 5% glycerol; Thermo Fisher Scientific, Inc., Waltham, MA, USA), followed by centrifugation at 12,879 x g for 15 min at 4°C to obtain cell extracts. Subsequently, 250 µl of albumin removal resin (Pierce™ Albumin Depletion kit; Thermo Fisher Scientific, Inc.) was added to the lysate and left at 4°C overnight. The samples were further centrifuged at 12,879 x g for 15 min at 4°C, the supernatant was subsequently collected, and protein content was measured according to Pierce® 660 nm Protein Assay reagent protocol (Thermo Fisher Scientific, Inc.) and NanoDrop 2000 (Thermo Fisher Scientific, Inc., Wilmington, DE, USA).

**Cell culture.** The metastatic breast cancer cell line, MDA-MB-231 was obtained from American Type Tissue Culture Collection (ATCC; Manassas, VA, USA). The MDA-MB-231 cells were sub-cultured and maintained in T75 flasks containing Dulbecco's modified Eagle's media (DMEM; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), supplemented with 10% fetal bovine serum (FBS) and 1% antibiotics (penicillin 10 U/ml and streptomycin 10 mg/ml). Cells were incubated at 37°C and 5% CO₂. Cells were used at 70-80% confluency for the experiments.

**Western blot analysis.** Like tissue lysates, MDA-MB-231 cell extracts were also prepared after the addition of cell lysis buffer, sonication, and centrifugation (at 12,879 x g for 15 min at 4°C). For western blot analysis, an equal amount (20-30 µg) of protein from tissue and cell lysates were loaded in 10% polyacrylamide gels and separated by using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The proteins were then transferred onto a 0.4 µm nitrocellulose membrane. Subsequently, the membranes were incubated with 5% milk blocking solution, followed by, primary solution of anti-PKC-ζ (SC-17781; 1:1,000; Santa Cruz Biotechnology, Dallas, TX, USA; and 9372s; 1:1,000; Cell Signaling Technology, Danvers, MA, USA), anti-Ras homolog gene family member A (RhoA; ab54835, 1:4,000; Abcam, Cambridge, UK) and anti-Rac1 (4651s; 1:1,000; Cell Signaling Technology) in 5% bovine serum albumin (BSA). Finally, the membranes were incubated with secondary antibodies. All the secondary antibodies (anti-rabbit and anti-mouse) were obtained from Bio-Rad Laboratories, Hercules, CA, USA (cat. no. 170-6515 and cat. no. 170-6516; 1:2,000). The immunoreactive bands were then visualized by chemiluminescence reaction, according to the manufacturer's instructions (SuperSignal™ West Pico PLUS Chemiluminescent Substrate; Thermo Fisher Scientific, Inc.). A monoclonal antibody to β-actin (SC-1616; Santa Cruz Biotechnology) was used as a loading control.
Western blot and immunohistochemistry analysis of PKC-ζ expression in normal and malignant tissues. Malignant tissues were evaluated for the expression of PKC-ζ. (A) We ran 20-30 µg of tissue lysate and probed with a PKC-ζ antibody. (B) The ratios of PKC-ζ to β-actin in healthy tissue and the four subtypes of malignant breast tissue were derived using the densitometry. The white bar (healthy) represents the control and the error bars represent the standard error. The standard deviation, a Student’s t-test (P<0.05) and a one-way ANOVA was used to evaluate the western blot data as well as the post-hoc Tukey’s HSD test (P<0.01), Scheffé multiple comparison (P<0.05), Bonferroni (P<0.01) and Holm (P<0.01). Statistical tests showed no meaningful relationship between the healthy and LCIS, or the ILC and DCIS. * statistically relevant relationship between normal and IDC breast tissue. (C) FFPE samples were probed with PKC-ζ and stained for immunohistochemistry. The scoring was based on the abundance or lack thereof PKC-ζ expression: Score: 0, no expression; 1, weak expression; 2, moderate expression; 3, abundant expression; 3 plus (+), strong expression. Image original magnification, ×20. LCIS, lobular carcinoma in situ; ILC, invasive lobular carcinoma; IDC, invasive ductal carcinoma; DCIS, ductal carcinoma in situ; PKC-ζ, protein kinase C-ζ; FFPE, formalin-fixed paraffin-embedded tissues.

**Densitometry.** The densitometry was performed using Image J (National Institutes of Health, Bethesda, MD, USA) software by the subtraction of background noise from the density of each band to derive the corrected intensity. All samples were normalized based on the intensity of β-actin bands on each blot.

**Immunohistochemistry.** FFPE tissues received from CHTN were sent to the Tissue Core, Moffitt Cancer Center (Tampa, FL, USA). Two different patient tissues were selected for each subtype (normal, LCIS, ILC, DCIS, and IDC) based on the criteria mentioned previously, with a total N=10. Briefly, tissues were stained with haematoxylin and eosin (H&E), and pathology quality control (PQC) were performed by a Tissue Core pathologist to confirm breast tissue subtype and diagnosis. The slides were prepared and stained with antibodies for PKC-ζ (ab59364; 1:1,000; rabbit polyclonal; Abcam). A uterine carcinoma specimen was selected as a positive control based on antibody data sheet and the Human Protein Atlas recommendations. Slides were stained using a Ventana Discovery XT automated system (Ventana Medical Systems, Tucson, AZ, USA) as per the manufacturer’s protocol with proprietary reagents. Briefly, slides were deparaffinized on the automated system with EZ Prep solution (Ventana Medical Systems). The heat-induced antigen retrieval method (CC1 standard) was used with the PKC-ζ primary rabbit antibody (Ventana Medical Systems). This antibody that reacts to the human isoform of PKC-ζ was used at a 1:1,000 concentration in Dako antibody diluent (Dako; Agilent Technologies, Inc., Santa Clara, CA, USA) and incubated for 32 min. The Ventana Omnimap Anti-Rabbit Secondary Antibody (Ventana Medical Systems) was used for 16 min. The detection system used was the Ventana ChromoMap kit and slides were then counterstained with haematoxylin. Slides were subsequently dehydrated and cover-slipped as per normal laboratory protocol. The Moffitt Cancer Center Tissue Core pathologist selected the optimal condition, titration, and incubation time to be used on the control and the breast selected slides. Subsequently, the pathologist evaluated the slides using the combinative semi quantitative scores (score, 0-3) (14). Images were taken on a light microscope Olympus BX51 (Olympus Corp., Tokyo, Japan).

**Knockdown of PKC-ζ for invasion pathway analysis.** Human breast cancer cells MDA-MB-231 were grown in 100 mm plates and transfected with 20 nM of scrambled RNA and siPRKCZ (5'-GCAUGAGCGAGGUAUUGACUGG-3', SR303747A; Origene, Rockville, MD, USA) for 48 h. Cells were lysed as previously described and the lysates were run on western blots.

**Cell invasion assay by crystal violet staining of invaded cells.** Cells were serum starved for 24 h, followed by detachment and plating into the upper chamber of a 96-well 8 µm Transwell permeable support, coated with 0.5X basement membrane extract (BME; both Corning Inc., Corning, NY, USA) for the evaluation of invasion. Serum (10%) containing media was loaded into the receiver plate (lower chamber) as a chemoattractant. MDA-MB-231 cells at the upper chamber media was loaded into the receiver plate (lower chamber) as a chemoattractant. MDA-MB-231 cells at the upper chamber were transfected with 20 nM siPRKCZ for 24 h. Four experimental treatment groups for the cells were performed: Control (non-treated), Si-Tran (transfection reagent), scrambled siRNA (random RNA) and siRNA for PRKCZ (for knockdown of PKC-ζ protein expression). The cells were treated with the transfection reagent (Si-Tran) and universal scrambled RNA to establish the effect of targeted small interfering RNA (siPRKCZ) only. The invasive cells that passed into the lower chamber were then fixed with 4% paraformaldehyde, stained with 2% crystal violet in 2% ethanol, washed with distilled
SMALLEY et al: ANALYSIS OF PKC-ζ PROTEIN LEVELS IN BREAST TISSUE SAMPLES

Table I. The selection of breast specimens with pathological characteristics.

| LN Grade/stage | ER | PR | Histology | Race | PKC-ζ expression | Number of patient samples |
|----------------|----|----|-----------|------|------------------|--------------------------|
| NA NA NA NA    | NA | NA | Normal    | Black| No               | 9                        |
| NA NA NA NA    | NA | NA | Normal    | NA   | No               | 4                        |
| NA NA NA NA    | NA | NA | Normal    | White| No               | 15                       |
| NA NA NA NA    | NA | NA | LCIS      | Black| No               | 1                        |
| + II/III - -   | -  | LCIS| White    | No   | 1                |
| + II/III + +   | LCIS| White| Yes     | 1    |
| NA NA NA NA    | NA | NA | ILC      | Black| No               | 1                        |
| - II/III + +   | ILC| White| No      | 1    |
| + III/III + +  | ILC| NA   | Yes     | 1    |
| NA NA NA NA    | NA | NA | ILC      | NA   | Yes              | 1                        |
| - NA NA NA     | NA | NA | ILC      | White| Yes              | 1                        |
| + II/III + +   | ILC| White| No      | 1    |
| NA NA NA NA    | NA | NA | IDC      | Black| No               | 1                        |
| + NA - NA      | IDC| Black| No      | 1    |
| - I/III + +    | IDC| White| No      | 1    |
| NA III/III NA  | NA | NA | IDC      | White| No               | 1                        |
| NA NA + -      | IDC| White| No      | 1    |
| NA NA + +      | IDC| Black| Yes     | 1    |
| - II/III NA NA | IDC| NA   | Yes     | 1    |
| + III/III NA NA| IDC| NA   | Yes     | 1    |
| + III/III NA NA| IDC| NA   | Yes     | 1    |
| NA NA + -      | IDC| NA   | Yes     | 1    |
| NA NA NA NA    | IDC| NA   | Yes     | 1    |
| - III/III - -  | IDC| NA   | Yes     | 1    |
| + NA NA -      | IDC| NA   | Yes     | 1    |
| + NA NA +      | IDC| NA   | Yes     | 1    |
| + NA NA NA     | IDC| NA   | Yes     | 1    |
| - NA NA NA NA  | IDC| NA   | Yes     | 1    |
| NA NA NA NA    | IDC| NA   | Yes     | 1    |
| - NA NA NA NA  | IDC| NA   | Yes     | 1    |
| + NA NA +      | IDC| Black| Yes     | 2    |
| - NA NA NA     | IDC| White| Yes     | 1    |
| + NA NA +      | IDC| White| Yes     | 1    |
| + NA NA NA     | IDC| White| Yes     | 1    |
| NA I/III NA NA | IDC| White| Yes     | 1    |
| NA NA - -      | IDC| White| Yes     | 1    |
| NA NA + -      | IDC| White| Yes     | 2    |
| NA NA NA NA    | IDC| NA   | Yes     | 3    |
| NA NA NA NA    | DCIS| Black| No      | 4    |
| NA NA NA NA    | DCIS| NA   | No      | 4    |
| - NA NA NA NA  | DCIS| Black| Yes     | 1    |

Tissue specimen were selected as described in material and methods and further sorted by the presence of PKC-ζ protein. LN, lymph node; ER, estrogen receptor; PR, progesterone receptor; PKC-ζ, protein kinase C-ζ; LCIS, lobular carcinoma in situ; ILC, invasive lobular carcinoma; IDC, invasive ductal carcinoma; DCIS, ductal carcinoma in situ; NA, not available.

Water and photographs were captured after drying using a light microscope Motic AE31E. 

Phalloidin staining of filamentous actin (F-actin). Human breast cancer cells MDA-MB-231 (1x10^4 cells) were grown
Table II. The status of PKC-ζ in malignant and healthy breast tissue.

| Tissue type | Not present | Weakly present | Positively present |
|-------------|-------------|----------------|--------------------|
| Normal tissue | 29          | 1              | 2                  |
| LCIS        | 2           | 1              | 0                  |
| ILC         | 8           | 4              | 1                  |
| DCIS        | 5           | 0              | 1                  |
| IDC         | 6           | 5              | 18                 |

Healthy breast tissue was obtained from breast reductions or the area adjacent to a patient's malignant tumors. Malignant tumors were either LCIS, ILC, DCIS, or IDC. The expression of PKC-ζ was evaluated as not present (ratio 0), weakly present (ratio <0.01) and positively present (ratio >0.01). LCIS, Lobular carcinoma in situ; ILC, invasive lobular carcinoma; DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; PKC-ζ, protein kinase C-ζ.

PKC-ζ protein levels are higher in invading breast cancer subtypes. To compare the expression of PKC-ζ in non-invading tissues and invading tissues, western blot and immunohistochemistry were performed. Western blot analysis data showed that PKC-ζ protein expression was higher in IDC when compared to the ILC, LCIS and the DCIS (Fig. 1A and B). According to immunohistochemistry findings, breast specimens were scored for the expression of PKC-ζ by the pathologist (Fig. 1C). Normal tissue had no to moderate expression (score, 0.2), LCIS had abundant expression (scores, 3.3), ILC had moderate to strong expression (scores, 2.3+), DCIS had moderate to abundant expression (scores, 2.3), and IDC had abundant to strong expression (scores, 3.3+). The most robust expression was found to be in IDC and ILC represented by the 3+ score. However, ILC was found to have moderate to strong expression, whereas IDC was found to have abundant to strong expression. These findings suggest that PKC-ζ is found higher in invading tissues when compared to non-invading tissues and more so in IDC when compared to ILC. These data suggest that the stage between in situ and invading malignancy can be correlated to an increased PKC-ζ protein expression.

PKC-ζ and E-cadherin levels in tissue specimens. Since the decreased expression of E-cadherin is indicative of a more aggressive phenotype, the relationship between PKC-ζ and E-cadherin protein levels was studied. Western blot analysis was used in the context of probing for PKC-ζ and E-cadherin in IDC breast tissues (Fig. 2A). We randomly selected 8 samples out of the 29 IDC tissue specimen to illustrate the data. We could not establish a significant relationship between PKC-ζ expression and E-cadherin expression in IDC samples. Our
linear regression test (Fig. 2B) showed no significance (P<0.05) between the expressions of PKC-ζ and E-cadherin protein levels in 20 randomly selected IDC breast tissue samples. The N value was too low to take into consideration for LCIS, ILC and DCIS. Normal breast tissues were not taken into consideration since the PKC-ζ expression was only found in 3 samples out of 32. However, our investigation established the relationship between E-cadherin protein expression and nuclear grade diagnosis (Fig. 2C). The Scarff-Bloom-Richardson scale data was derived from the pathology reports (summarized in Tables I and V). The results show that E-cadherin protein expression had an inverse relationship to nuclear grade diagnosis. Even though the PRKCZ gene is not one of the top mutated genes in breast cancer (carcinomas and carcinomas in situ), CDH1 is on the top of the list (Table VI) (3).

**PRKCZ gene silencing decreases the invasion of breast cells.** To investigate the effects of PKC-ζ inhibition on the invasive behavior of breast cancer cells, a Transwell invasion assay and immunostaining of F-actin were performed. When compared to the control, PKC-ζ knockdown decreased the invasion of breast cancer cells by 60% and was significant (Student’s t-test P<0.05, one-way ANOVA Tukey HSD P-value 0.0029646, P<0.01; Scheffé P-value 0.0049622, P<0.01; Bonferroni P-value 0.0040067, P<0.01 and Holm P-value 0.0040067, P<0.01) (Fig. 3A and B). In addition, the levels of two important components of metastatic pathways, Rac1 and RhoA, were also decreased dramatically (Fig. 3C). Moreover, MDA-MB-231 breast cancer cells were fixed and stained with phalloidin probe to visualize the impacts of PRKCZ gene silencing on F-actin organization. The silencing of PRKCZ caused the reorganization of F-actin around the cell cytoskeleton (Fig. 4). Taken together, these data advance the theory that PKC-ζ modulates the invasive behavior of breast cancer cells by the regulation of invasion through the Rac1/RhoA pathway and cytoskeleton filaments.

### Table III. Chi-square statistical analysis results of normal and malignant breast subtypes (normal, LCIS, ILC, DCIS and IDC; N=83)

| Variable            | Normal | LCIS | ILC | DCIS | IDC | Row totals | Chi-square | P-value |
|---------------------|--------|------|-----|------|-----|------------|------------|---------|
| PKC-ζ present       | 3      | 1    | 5   | 1    | 23  | 33         | 32.6715    | <0.00001 |
| PKC-ζ absent        | 29     | 2    | 8   | 5    | 6   | 50         |            |         |
| Column totals        | 32     | 3    | 13  | 6    | 29  | 83 (grand total) |

Values were considered to be statistically significant at P<0.01. The Chi-square analysis compared the absence or presence of PKC-ζ expression (determined by western blots) in different breast tissue specimens. LCIS, lobular carcinoma in situ; ILC, invasive lobular carcinoma; DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; PKC-ζ, protein kinase C-ζ.

### Table IV. Chi-square statistical analysis results of estrogen receptor expression (N=25).

| Variable            | ER+ | ER- | Row totals | Chi-square | P-value |
|---------------------|-----|-----|------------|------------|---------|
| PKC-ζ present       | 10  | 6   | 16         | 0.0434     | 0.834969 |
| PKC-ζ absent        | 6   | 3   | 9          |            |         |
| Column totals        | 16  | 9   | 25 (grand total) |

Values were considered to be not statistically significant at P<0.10. The Chi-square analysis compared the absence and presence of PKC-ζ expression (determined by western blot) with the absence (-) and presence (+) of estrogen receptors (ER) in different breast tissue specimens. PKC-ζ, protein kinase C-ζ.

### Table V. Chi-square statistical analysis results of Scarff-Bloom-Richardson grading (N=22).

| Variable            | NG1 | NG2 | NG3 | Row totals | Chi-square | P-value |
|---------------------|-----|-----|-----|------------|------------|---------|
| PKC-ζ present       | 4   | 4   | 5   | 13         | 0.2        | 0.90485 |
| PKC-ζ absent        | 3   | 2   | 4   | 9          |            |         |
| Column totals        | 7   | 6   | 9   | 22 (grand total) |

Values were considered to be not statistically significant at P<0.01. The Chi-square analysis compared the absence and presence of PKC-ζ expression (determined by western blot) with nuclear grades 1-3 (NG1-NG3) in different breast tissue specimens. PKC-ζ, protein kinase C-ζ.
Discussion

Previously, Yin et al showed that the expression of PKC-ζ was higher in invading breast tissues compared to samples uncomplicated with tumors and the highest PKC-ζ protein expression existed in stage III human breast ductal carcinomas (17). Likewise, Paul et al concluded that the depletion of PKC-ζ reduced the invasive behaviors of MDA-MB-231 cells by upregulating epithelial markers such as Zonula occludens-1 (ZO-1) and E-cadherin (6). They also found that PKC-ζ activation (phosphorylated PKC-ζ levels) was found higher in invasive tissues (i.e., IDC and metastatic tissues) when compared to non-invasive tissues (DCIS). PKC-ζ expression did not significantly change with the presence
or absence of receptors (ER and HER2) (6). Our western blots and Chi-squared analysis (Fig. 1A and B; Table IV) support these findings. They performed a PKC-ζ knockdown mouse study and found that the depletion of PKC-ζ leads to an approximately 50% reduction in primary tumor growth compared to the control within five weeks (6). Similarly, our western blot analysis and immunohistochemistry data of IDC and ILC (Fig. 1A-C) suggest that PKC-ζ might also be a novel component in pathways that affect cancer cell invasion and metastasis.

PKC-ζ assists a transcription factor (NFκB-p65) that downregulates targets such as E-cadherin and ZO-1 (6). In addition, decreased E-cadherin levels cause the cells to no longer adhere to the extracellular matrix causing the cells to migrate, invade, or metastasize (6). Moreover, Chua et al showed that NF-xB induction elevated expression of Zinc finger E-box binding homeobox 1 and 2 (ZEB-1 and ZEB-2) which ultimately repressed the E-cadherin levels (7). In our investigation, we could not establish a statistical relationship between PKC-ζ and E-cadherin protein expression in IDC (Fig. 2B) as per the linear regression analysis. However, previous studies illustrated an increase in E-cadherin levels in PKC-ζ knockdown MDA-MB-231 cells (6).

In addition, our findings showed an increased expression of PKC-ζ in IDC tissues when compared to other subtypes (Fig. 1A-C) which may be because of the difference in pathological features of ductal and lobular tumors. Ductal carcinomas are lined with a two-layered stratified cuboidal epithelium resting on the basement membrane. This cuboidal epithelium contains tight junctions where E-cadherins are located and play a central role in cell-to-cell adhesion (18). In contrast, lobular carcinomas vary in terms of molecular and genetic aberrations. Lobular carcinomas are epithelial-like, growing individually in sheets or in a single file (4). In our investigation, E-cadherin levels were also compared to the nuclear grade listed on the pathology report (Fig. 2C; Table V), which supports the previous studies that described a decline in E-cadherin as a part of the epithelial to mesenchymal transition leads to metastasis (7,19).

Table VI. Top mutated genes in all breast cancer types.

| Protein function | Protein product | Gene | Chromosome Location | Protein product | Highest percentage mutation (%)) | Mutation type | Percentage of mutated samples tested (%) | Mutation type |
|------------------|------------------|------|---------------------|------------------|----------------------------------|--------------|----------------------------------------|--------------|
| Phosphorylates certain signaling molecules | Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α | PIK3CA | 3q26.3 | 98.97 | Substitution missense | 27 |
| Inhibits cell cycle | Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit β | PTEN | 10q23.3 | 50.30, 28.70 | Substitution missense, other | 24 |
| Regulates transcription initiation | Peroxisome proliferator-activated receptor γ | PPARG | 12q13.1 | 71.04 | Substitution missense, deletion frameshift | 20 |
| E-cadherin (Cadherin 1) | E-cadherin | CDH1 | 16q22.1 | 28.07, 18.42, 17.54 | Substitution missense, deletion frameshift | 11 |

This table was created after a review of the Catalogue of Somatic Mutations in Cancer database.
reduced the invasion of MDA-MB-231 breast cancer cells by 60% (P<0.05) when compared to control (Fig. 3A and B). In addition, there was a decreased expression of both Rac1 and RhoA in siPRKCZ transfected MDA-MB-231 breast cancer cells compared to control (Fig. 3C). Furthermore, our immunostaining analysis of F-actin illustrated that actin filaments were nicely organized around the cells with the inhibition of PKC-ζ (Fig. 4). Hence, PKC-ζ may play an essential role in the invasion and migration of breast cancer cells by the regulation of RhoA and Rac1 pathways.

To conclude, our findings suggest that PKC-ζ is found to be most abundant in invading tissue subtypes and may be a functional component of invasion pathways such as Rac1 and RhoA. The use of PKC-ζ-specific inhibitors could be used to correlate the decrease in expression or functionality of PKC-ζ with the decrease in invasive behavior in breast cancer.

Acknowledgements

The authors would like to thank the Tissue Core, Moffitt Cancer Center (Tampa, FL, USA) for their assistance. Tissue samples were provided by the NCI Cooperative Human Tissue Network.

Figure 4. Organization of F-actin upon the knockdown of PKC-ζ. MDA-MB-231 breast cancer cells were treated with SiTran, scrambled RNA and siPRKC-ζ for 24 h. The cells that received no treatment were used as the control. These cells were then stained with 1X Phalloidin-iFluor 594 and counterstained with DAPI. Scale bar, 100 µm. Original magnification, x20. DAPI, 4',6-diamidino-2-phenylindole; F-actin, filamentous actin; PKC-ζ, protein kinase C-ζ.

Funding

This study was funded by the University of South Florida (Tampa, FL, USA) Foundations 42-0142. The authors would like to acknowledge the financial contributions from the William and Ella Owens Medical Research Foundation, Alaska Run for Women, Save the Ta-Tas Foundation, Mary Ewell Dickens Foundation, Yolanda and Salvatore Gigante Charitable Foundation Trust, Daniel Tanner Foundation, Frederick H. Leonhardt Foundation and the Charles and Ann Johnson Foundation.

Availability of data and materials

The datasets we used and/or analyzed during the current study are available from the corresponding authors upon reasonable request. The datasets we generated and/or analyzed during the current study are available from the COSMIC repository at https://cancer.sanger.ac.uk/cosmic.

Authors' contributions

TS contributions include tissue selection and fractionation, western blot analysis, densitometry analysis, statistical analyses,
pathway analysis and writing. SMAI contributions include the invasion assay, phallloidin staining, and writing. CA contributions include preliminary western blot analysis. AA contributions to the paper include statistical analysis of E-cadherin expression and nuclear grade. MAD contributions to the paper include concept, design, writing, editing, resources, supervision and funding acquisition. The authors read and approved the final manuscript.

Ethics approval and consent to participate

The right to informed consent was waived by the Ethics committee of the University of South Florida.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author information

TS is currently a graduate student at the University of South Florida, Department of Chemistry. She is working on the second year of her PhD and continues to work on ovarian cancer and breast cancer.

References

1. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin 66: 7-30, 2016.
2. Kuhn E: Quick Guide for Most Commonly Used Breast Cancer Statements. Susan G. Komen: 10-11, 2015.
3. COSMIC: Catalogue of somatic mutations in cancer, 2016.
4. Ruibal A, Núñez MI, del Rio M, Arias J, Martínez MI, Rabadán J and Tejerina A: Clinical-biological differences between invasive ductal carcinomas and breast lobular carcinomas. Preliminary results. Rev Esp Med Nucl 18: 84-87, 1999.
5. Hoesel B and Schmid JA: The complexity of NF-xB signaling in inflammation and cancer. Mol Cancer 12: 86, 2013.
6. Paul A, Danley M, Saha B, Tawfik O and Paul S: PKC-zeta promotes breast cancer invasion by regulating expression of E-Cadherin and Zonula Occludens-1 (ZO-1) via NFkB-p65. Sci Rep 5: 12520, 2015.
7. Chua HL, Bhat-Nakshatri P, Clare SE, Morimiya A, Badve S and Nakshatri H: NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: Potential involvement of ZEB-1 and ZEB-2. Oncogene 26: 711-724, 2007.
8. Singhai R, Patil VW, Jaiswal SR, Patil SD, Tayade MB and Patil AV: E-Cadherin as a diagnostic biomarker in breast cancer. N Am J Med Sci 3: 227-233, 2011.
9. Hirai T and Chida K: Protein kinase Czeta (PKCzeta): Activation mechanisms and cellular functions. J Biochem 133: 1-7, 2003.
10. Islam SMA, Patel R and Acevedo-Duncan M: Protein Kinase C-zeta stimulates colorectal cancer cell carcinogenesis via PKC-ζ/Rac1/Pak1/β-Catenin signaling cascade. Biochim Biophys Acta Mol Cell Res 1865: 650-664, 2018.
11. Wu J, Liu S, Fan Z, Zhang L, Tian Y and Yang R: A novel and selective inhibitor of PKC ζ potently inhibits human breast cancer metastasis in vitro and in mice. Tumour Biol 83: 8391-8401, 2016.
12. Lin YM, Su CC, Su WW, Hwang JM, Hsu HH, Tsai CH, Wang YC, Tsai FJ, Huang CY, Liu YJ and Chen LM: Expression of protein kinase C isoforms in cancerous breast tissue and adjacent normal breast tissue. Chin J Physiol 55: 55-61, 2012.
13. Schöndorf T, Kurbacher CM, Becker M, Warm M, Kolhagen H and Göhring UF: Heterogeneity of proteinkinase C activity and PKC-ζ expression in clinical breast carcinomas. Clin Exp Med 1: 1-8, 2001.
14. Kim SW, Roh J and Park CS: Immunohistochemistry for pathologists: Protocols, pitfalls, and Tips. J Pathol Transl Med 50: 411-418, 2016.
15. GraphPad Software: GraphPad QuickCalcs: Linear regression calculator. 2018.
16. Social science statistics: Chi-square test calculator-up to 5x5 contingency table. 2018.
17. Yin WJ, Lu JS, Di GH, Lin YP, Zhou LH, Liu GY, Wu J, Shen KW, Han QX, Shen ZZ and Shao ZM: Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. Breast Cancer Res Treat 115: 325-333, 2009.
18. Hugo HJ, Gunasinghe NPAD, Hollier BG, Tanaka T, Blick T, Toh A, Hill P, Gilles C, Waltham M and Thompson EW: Epithelial requirement for in vitro proliferation and xenograft growth and metastasis of MDA-MB-468 human breast cancer cells: Oncogenic rather than tumor-suppressive role of E-cadherin. Breast Cancer Res 19: 86, 2017.
19. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES and Weinberg RA: Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 68: 3645-3654, 2008.
20. Lauffenburger DA: Cell motility. Making connections count. Nature 383: 390-391, 1996.
21. Raftopoulou M and Hall A: Cell migration: Rho GTPases lead the way. Dev Biol 265: 23-32, 2004.
22. Lawson CD and Ridley AJ: Rho GTPase signaling complexes in cell migration and invasion. J Cell Biol 217: 447-457, 2018.
23. Small JV, Stradal T, Vignali E and Rottner K: The lamellipodium: Where motility begins. Trends Cell Biol 12: 112-120, 2002.
24. Nobes CD and Ridley AJ: Rho GTPases control polarity, protrusion, and adhesion during cell movement. J Cell Biol 144: 1235-1244, 1999.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.